Argent BioPharma (ASX: RGT) has commenced supplying a cannabinoid-based active pharmaceutical ingredient (API) to treat patients with drug-resistant epilepsy at Slovenia’s largest hospital, University Medical Centre Ljubljana (UMCL). Argent BioPharma is a pharmaceutical company focused on developing and commercialising cannabinoid-based therapies. The company’s flagship product is CannEpil, a cannabinoid-based therapy for neurological conditions.
Following a successful pilot program, the API will be transitioned to routine use at the paediatric clinic within UMCL. This allows neurologists to dispense recommended formulations for young patients according to established protocols. CannEpil has previously demonstrated clinical utility in Ireland and other European markets, allowing Argent to refine dosing, safety monitoring, and supply logistics to accelerate regulatory alignment and physician uptake.
The supply agreement is the result of a multi-year collaboration between Argent and University Medical Centre, as well as Slovenia’s Ministry of Health and Agency for Medicinal Products and Medical Devices (JAZMP). Argent has provided JAZMP with pre-clinical data, GMP validation, and clinical experience with CannEpil, which helped shape the national framework permitting hospital compounding of cannabinoid formulations for neurological conditions.
According to Argent Chair Roby Zomer, the supply agreement validates Argent’s ability to convert pilot projects into full hospital programs and highlights its leadership in shaping cannabinoid regulations alongside national health authorities. Senior consultant neurologist Dr David Neubauer is confident the API will advance the clinic’s work, providing an evidence-based option for complex epilepsy cases.
